Globe Newswire10.26.18
InspireMD Inc., developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced that its CGuard Embolic Prevention System (EPS) has been granted regulatory approval by COFEPRIS (the Mexican Ministry of Health) for commercial sale in Mexico.
“The expansion of our commercial footprint into new key geographies is a fundamental component of our growth strategy,” said James Barry, Ph.D., CEO of InspireMD. “We are pleased to have received regulatory approval for the commercial sale of CGuard EPS in Mexico, and very grateful for the support provided by our distribution partner, LevBeth Medical, throughout this rigorous approval process.”
Mr. Mauro Levinton, Managing Director of LevBeth Medical S.A. de C.V, noted, “We have been eagerly following the clinical data being generated on CGuard as it continues to demonstrate its superiority over conventional stents, and we look forward to launching this innovative product and technology and making it available to patients in Mexico who suffer from carotid artery disease.”
InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for treatment of carotid arter disease by providing outstanding acute results and durable stroke free long-term outcomes. InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
“The expansion of our commercial footprint into new key geographies is a fundamental component of our growth strategy,” said James Barry, Ph.D., CEO of InspireMD. “We are pleased to have received regulatory approval for the commercial sale of CGuard EPS in Mexico, and very grateful for the support provided by our distribution partner, LevBeth Medical, throughout this rigorous approval process.”
Mr. Mauro Levinton, Managing Director of LevBeth Medical S.A. de C.V, noted, “We have been eagerly following the clinical data being generated on CGuard as it continues to demonstrate its superiority over conventional stents, and we look forward to launching this innovative product and technology and making it available to patients in Mexico who suffer from carotid artery disease.”
InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for treatment of carotid arter disease by providing outstanding acute results and durable stroke free long-term outcomes. InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.